Poor survival linked to Puerto Rican women with triple-negative breast cancer subtype

Share this article:
Puerto Rican women with triple-negative breast cancer subtype have an increased risk of breast cancer death, according to a study presented at the 2010 AACR Conference on The Science of Cancer Health Disparities.

For the study, researchers analyzed data for 974 female patients with invasive breast cancer, among which 16.6% were triple negative, neither overexpressing HER2neu nor receptive to estrogen or progesterone.

The scientists reported that the risk of breast cancer death for Puerto Rican women who had the triple-negative breast cancer subtype was more than twice as high compared to women with other tumor subtypes. In addition, women who were age 50 years or younger at the time of diagnosis and had regional/distant disease were also more likely to die as a result of their breast cancer.

“Findings, which were consistent with results described in previous studies of U.S. populations, will be useful in the development of cancer control strategies in Puerto Rico and may have an impact on future studies of targeted therapies to improve breast cancer survival in other Hispanic populations,” concluded Ana Ortiz Martinez, MPH, PhD, associate professor and researcher at the University of Puerto Rico Cancer Center and the department of biostatistics and epidemiology, Graduate School of Public Health, University of Puerto Rico.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Y-90 radioembolization: A new treatment for hepatic metastases from breast cancer

Yttrium-90 radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver.

More sensitive testing may better define prognosis and treatment for leukemia

Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.